| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10743193 | Maturitas | 2015 | 5 Pages |
Abstract
Recent clinical data supports a role for T in BCA prevention. Women with symptoms of hormone deficiency treated with pharmacological doses of T alone or in combination with anastrozole (A), delivered by subcutaneous implants, had a reduced incidence of BCA. In addition, T combined with A effectively treated symptoms of hormone deficiency in BCA survivors and was not associated with recurrent disease. Most notably, TÂ +Â A implants placed in breast tissue surrounding malignant tumors significantly reduced BCA tumor size, further supporting T direct antiproliferative, protective and therapeutic effect.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
R. Glaser, C. Dimitrakakis,